SCHEMBL5240397

SCHEMBL5240397

OC1NCCC2CCCC=C21

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28047878 0.77
SCHEMBL27882958 0.74
SCHEMBL901128 0.71 ESR2 (0.31)
SCHEMBL14879909 0.71 ESR2 (0.31)
Ammonia Solution, Strong SCHEMBL28327714 0.69
SCHEMBL27446512 0.68 ALDH1A1 (0.31)
SCHEMBL3635389 0.66
SCHEMBL180087 0.65
SCHEMBL6206708 0.63 GAA (0.35)
SCHEMBL6206710 0.63 GAA (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107428747-A Substituted pyridobenzodiazepine ketone derivative and use thereof 拜耳制药股份公司 2017-12-01 CN disclosed
WO-2007092391-A1 ANDROGEN RECEPTOR MODULATORS AND METHODS OF TREATING DISEASE USING THE SAME ACADIA PHARMACEUTICALS INC. (US) 2007-08-16 WO disclosed
EP-1756101-A2 ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME Acadia Pharmaceuticals Inc. (US) 2007-02-28 EP disclosed
WO-2005115361-A2 ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME ACADIA PHARMACEUTICALS INC. (US) 2005-12-08 WO disclosed
US-20030105102-A1 Oxo-substituted compounds, process of making, and compositions and methods for inhibiting PARP activity GUILFORD PHARMACEUTICALS INC. 2003-06-05 US disclosed
US-20020022636-A1 OXO-SUBSTITUTED COMPOUNDS, PROCESS OF MAKING, AND COMPOSITIONS AND METHODS FOR INHIBITING PARP ACTIVITY GUILFORD PHARMACEUTICALS INC. 2002-02-21 US disclosed
US-6235748-B1 CENTRAL NERVOUS SYSTEM DISORDERS; CARDIOVASCULAR DISORDERS GUILFORD PHARMACEUTICALS INC. 2001-05-22 US disclosed
EP-1009739-A2 OXO-SUBSTITUTED COMPOUNDS, PROCESS OF MAKING, AND COMPOSITIONS AND METHODS FOR INHIBITING PARP ACTIVITY GUILFORD PHARMACEUTICALS INC. (US) 2000-06-21 EP disclosed
WO-1999011624-A1 OXO-SUBSTITUTED COMPOUNDS, PROCESS OF MAKING, AND COMPOSITIONS AND METHODS FOR INHIBITING PARP ACTIVITY GUILFORD PHARMACEUTICALS INC. (US) 1999-03-11 WO disclosed